Navigation Links
BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Date:2/28/2008

BIRMINGHAM, Ala., Feb. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter and fiscal year 2007 financial results will be released on Tuesday, March 4, 2008. At 8:30 a.m. Eastern Time BioCryst will host a conference call and webcast to discuss the financial results and provide an update on the Company's programs and further clinical data. The call will be led by Jon P. Stonehouse, BioCryst's Chief Executive Officer, and Stuart Grant, BioCryst's Chief Financial Officer.

The webcast can be accessed by logging onto http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. To participate in the conference call, please dial 1-800-860-2442 (U.S.) or 1-412-858-4600 (international). The audio portion of the webcast will be archived and available for replay for 14 days.

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The Company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...COLUMBUS, Ohio, Nov. 30 The Ohio C...of the nation,s first minority business early-stag...land December 3, is called "Transforming the Lands...arly-Stage Capital Summit." It will feature severa...business leaders and local minority entrepreneurs....
(Date:11/30/2009)...NEW YORK, Nov. 30 The M...(MJFF) today announced $1.5 million in total award...ally disease-modifying therapies for Parkinson,s d...pproaches to Drug Discovery for Parkinson,s Diseas...poration, plc (NYSE: ELN ), a neuroscience-based...
(Date:11/30/2009)...ICAGO, Nov. 30 Dr. Jessica Torrent...ington University Medical Center in Washington, D....-Specific Gamma Imaging (BSGI) in clinical practic... of breast cancer today at the annual meeting of t..., "The purpose of the exhibit was to demonstrat...
(Date:11/30/2009)... PDS, a leader in providing smart and ...nnounces Pajama Pathology®, evolutionizing wor...lsquo;gold standard’ software used by 8 of t...ut on a ‘cost per slide’ basis. , ...ovember 30, 2009 -- PDS has announced another evol...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3
...nc. (NYSE: BRL ) today announced that the Company...e on Thursday, February 28 to discuss earnings,for...ded December 31, 2007.,The number to call from wit... 338- 1040 Internationally. A replay of the confer...ime on February 28 through 11:59PM Eastern,time Ma...
...gs, Inc. (Nasdaq: ADLS ), today announced that it...0:30 am (EST) on Tuesday, January 22,2008. The foc... that was,made yesterday by the US Food & Drug Adm...he Anti-Infective Drugs Advisory Committee to disc...for community acquired,pneumonia (CAP)., (Logo: ...
...cent comments by certain plaintiff law firms regar...te Genetics Corporation (the "Company") (OTC,Bulle...re without merit and,will be shown to be so in a c...e international law firm of Duane Morris LLP as it...se matters. Concurrently, the Company,will continu...
Other Biology Technology:Barr Will Host Calendar 2007 and Fourth Quarter Earnings Conference Call on February 28, 2008 2Barr Will Host Calendar 2007 and Fourth Quarter Earnings Conference Call on February 28, 2008 3Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development 2Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development 3CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 3
(Date:12/1/2009)... , NEW YORK, Dec. 1 iQor, a glo... services, was included in the 2009 InfoWorld 10...ric-enabled ERP system, TeQ21. This was the first ...ecognized among this prestigious list of companies...TeQ21 is completely transforming the way we do bus...
(Date:12/1/2009)...ness, like a bad cold, can spread among groups of ... University of California-San Diego and Harvard sh... study that has been following health conditions f...at lonely people tend to share their loneliness wi... disconnected people moves to the fringes of socia...
(Date:11/30/2009)... of scientists from The Forsyth Institute, the Uni...the Wadsworth Center, have used state-of-the-art t...of Treponema pallidum, the bacterium which causes ...e of the bacteria can now be shown in three dimens...thogen and reveals previously unknown features, wh...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Loneliness can be contagious 2Loneliness can be contagious 3Scientists gain new understanding of disease-causing bacteria 2Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 1Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 2Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 1Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 2Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 3IRIDEX Introduces Modular Multi Wavelength Laser Solution at the American Academy of Ophthalmology 5627 1IRIDEX Introduces Modular Multi Wavelength Laser Solution at the American Academy of Ophthalmology 5627 2IRIDEX Introduces Modular Multi Wavelength Laser Solution at the American Academy of Ophthalmology 5627 3IRIDEX Introduces Modular Multi Wavelength Laser Solution at the American Academy of Ophthalmology 5627 4
...ter deciding to create an electronic database, Roc...nd results database using an independent host, Cen...oche’s clinical trials can be accessed by anyone, ... is designed to give patients and healthcare provi...ms they can understand. , Ed Holdener, Head of Glo...
...n a protective lipid membrane. The membrane is stu... transport nutrients, ions, and water into and out...ls recognize each other in the body, and make the ...rsity have now mapped out nearly all of the membra...oli. Their study is published this week in Science...
...as found that a protein known for its role in gene...f initiating DNA repair. The study, published in t...ew targets for treatment of cancer. , Ze,ev Ronai...uction Program, and his colleagues found that the ... is activated by a protein kinase called ATM ("Ata...
Other Biology News:Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3New understanding of DNA repair may pave way to cancer treatments 2
...'s family of light scattering instruments. The HTm...ph and enables you to get multi-angle light scatte... easily installed in the oven of any Waters 150C, ...get three angles of light scattering data taken si...
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...es, for 10 chips, provides the reagents and suppli...ysis (picogram levels) with 10 chips on the Experi...1,250 microliters RNA gel, 20 microliters RNA High...ters RNA HighSens loading buffer, 100 microliters ...
Mouse Anti-Verotoxin II (Shiga-like) A subunit (SLT-2a) Monoclonal Antibody, Unconjugated, Clone 557 from Meridian Life Science, Inc.
Biology Products: